AZD5305 + carboplatin + paclitaxel

AZD5305 + carboplatin + paclitaxel is an **investigational combination therapy** targeting solid tumors, especially advanced ovarian cancer with homologous recombination repair deficiencies (such as BRCA1/2 mutations). AZD5305 is a next-generation, highly selective oral **PARP1 inhibitor** developed to maximize DNA damage in tumor cells while minimizing off-target effects associated with dual PARP1/2 inhibitors. Carboplatin is a **platinum-based DNA crosslinker** commonly used in solid tumor regimens, and paclitaxel is a **microtubule inhibitor** used broadly in cancer chemotherapy. Preclinical and early clinical data suggest that combining AZD5305 with carboplatin and paclitaxel increases antitumor efficacy compared to single agents, particularly in platinum-refractory ovarian cancer models, by enhancing DNA damage and cytotoxicity[1][2][3][4][5].